Among those consuming UPFs in high-income countries, intake varies significantly across age and socioeconomic status.

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.